search
Back to results

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

Primary Purpose

Distal Radius Fracture, Osteoporosis, Hip Fractures

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Reference Point Indentation
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Distal Radius Fracture

Eligibility Criteria

50 Years - 100 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Women with hip and wrist fractures within 2 weeks of presentation
  • Non-fracture controls

Exclusion Criteria:

  • Unable to undergo BMD by DXA or high-resolution peripheral quantitative computed tomography (HR-pQCT)
  • History of skeletal metastasis, primary hyperparathyroidism, Paget's disease, multiple myeloma
  • Treatment with bisphosphonate, estrogen (within previous 3 years), teriparatide therapy, calcitonin, selective estrogen receptor modulator (SERMs,within previous 3 years)
  • Use of glucocorticoids continuously for more than 3 months, use of anticonvulsants
  • Prior fracture in adulthood (>age 18) for healthy controls

Amendment to protocol added Arm 2, to include males >50 years with otherwise similar eligibility criteria.

Sites / Locations

  • Beth Israel Deaconess Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Post-menopausal women

Males over 50 years

Arm Description

We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

Outcomes

Primary Outcome Measures

Cortical bone tissue properties by reference point indentation
Osteoprobe measurement
Bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA)
DXA at the hip and spine

Secondary Outcome Measures

Full Information

First Posted
March 6, 2017
Last Updated
August 22, 2023
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Brigham and Women's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03076034
Brief Title
Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk
Official Title
Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 26, 2015 (Actual)
Primary Completion Date
August 8, 2025 (Anticipated)
Study Completion Date
November 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Brigham and Women's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA).
Detailed Description
The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as BMD. To test these hypotheses, The investigators propose two aims: Aim 1: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with hip fractures and non-fracture controls. The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent hip fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with hip fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders. Aim 2: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with distal radius fractures to non-fracture controls. The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent distal radius fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders. Successful completion of this project will address the need to better assess bone mechanical properties at the tissue level in order to accurately predict fracture risk. The study will provide novel information about possible clinical utility of minimally invasive, in vivo bone indentation measurements to measure bone strength and its relationship to fracture risk. Aim 3: An amendment to the protocol expanded the study population to now include males >50 years who present with distal radius fractures and those who present for a reason other than fracture (non-fracture controls). Hypotheses: Men >50 years with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Distal Radius Fracture, Osteoporosis, Hip Fractures

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Observational
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
190 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Post-menopausal women
Arm Type
Experimental
Arm Description
We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
Arm Title
Males over 50 years
Arm Type
Experimental
Arm Description
We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
Intervention Type
Device
Intervention Name(s)
Reference Point Indentation
Other Intervention Name(s)
Osteoprobe
Intervention Description
The "Osteoprobe": Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of ~375 µm.
Primary Outcome Measure Information:
Title
Cortical bone tissue properties by reference point indentation
Description
Osteoprobe measurement
Time Frame
Day 1
Title
Bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA)
Description
DXA at the hip and spine
Time Frame
Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women with hip and wrist fractures within 2 weeks of presentation Non-fracture controls Exclusion Criteria: Unable to undergo BMD by DXA or high-resolution peripheral quantitative computed tomography (HR-pQCT) History of skeletal metastasis, primary hyperparathyroidism, Paget's disease, multiple myeloma Treatment with bisphosphonate, estrogen (within previous 3 years), teriparatide therapy, calcitonin, selective estrogen receptor modulator (SERMs,within previous 3 years) Use of glucocorticoids continuously for more than 3 months, use of anticonvulsants Prior fracture in adulthood (>age 18) for healthy controls Amendment to protocol added Arm 2, to include males >50 years with otherwise similar eligibility criteria.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tamara Rozental, M.D.
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

We'll reach out to this number within 24 hrs